-
NMPA Announcement on Issuing 2 Guidance including the Guidance for Nomenclature of the Generic Names of Neurosurgical and Cardiovascular Surgical Devices
2021-08-25
The NMPA has organized to formulate the Guidance for Nomenclature for Generic Names of Neurosurgical and Cardiovascular Surgical Devices, and Guidance for Nomenclature for Generic Names of Devices for Medical Diagnosis, Examination and Monitoring, which were issued on August 25, 2021.
-
NMPA CDE Announcement on Issuing the Technical Guidance for Clinical Trials of Drugs for the Treatment of Acute Non-Variceal Upper Gastrointestinal Bleeding
2021-08-06
The Center for Drug Evaluation has organized to develop the Technical Guidance for Clinical Trials of Drugs for the Treatment of Acute Non-Variceal Upper Gastrointestinal Bleeding under the deployment of the National Medical Products Administration.
-
NMPA CDE Announcement on Issuing the Guidance for Immunogenicity Study of Generic Drugs of Low Molecular Weight Heparin (Interim)
2021-08-06
The CDE has organized to develop the Guidance for Immunogenicity Study of Generic Drugs of Low Molecular Weight Heparin (interim) under the deployment of the NMPA.
-
NMPA Notice on Matters Concerning the Registration of Drug-device Combination Products
2021-07-27
In accordance with relevant provisions for registration management of drugs and medical devices, matters concerning the registration of drug-device combination products are hereby announced on July 23 as follows.
-
NMPA Announcement on the Revision of the Package Insert of the Vitamin B6 Injection
2021-07-27
In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, NMPA decided to modify the items of [Adverse reactions] and [Contraindications] in the package inserts of Vitamin B6 injection.
-
NMPA Announcement on the Revision of the Package Insert of the Propranolol Tablets
2021-07-20
The NMPA decided to modify the items of [Precautions] in the package inserts of propranolol tablets. On July 15, relevant issues are hereby announced as follows.